In addition to verapamil, colchicine has also been shown to affect the ability of fibroblasts to make collagen. Have studies ever been done to determine whether or not local colchicine delivered via intralesional injection would have results similar, or better, than that of verapamil? Presumably this could deliver the drug to the site of the plaque, but without the systemic ill effects secondary to ingestion of oral colchicine.

The evidence supporting the use of oral colchicine is weak although Peyronie’s disease cells react favorable to colchicines in a test tube. The main requirement for the use of any medication as an intralesional agent is that it is safe when given intravenously (as some of the drug will be absorbed from the veins above and below the plaque). Colchicine has never been explored as an intravenous agent and therefore cannot be used intralesionally.